Navigation Links
Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY™ Drug-Eluting Coronary Stent
Date:1/24/2011

NATICK, Mass., Jan. 24, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Company's fourth-generation SYNERGY™ Coronary Stent.  The randomized, single-blind, non-inferiority trial will compare the SYNERGY Stent to the PROMUS Element™ Everolimus-Eluting Coronary Stent in patients with a single de novo native coronary artery lesion.  The trial enrolled 291 patients at 29 sites in Europe, Australia and New Zealand, and completed enrollment four months ahead of schedule.  

The SYNERGY Stent uses a bioabsorbable PLGA polymer and everolimus drug combination to create a thin, uniform coating confined to the outer surface of the stent.  Once the drug has been delivered, the bioabsorbable coating resorbs in three to six months, leaving behind only a bare-metal stent.  This technology is designed to provide the same degree of restenosis reduction as a conventional drug-eluting stent while offering faster and more complete vessel healing after stent implantation, which could potentially reduce the duration of required adjunctive medical therapies.  The SYNERGY Stent features the same proprietary platinum chromium alloy and innovative stent design used in the PROMUS Element Stent to enable thinner struts, increased flexibility and a lower profile while reducing recoil and improving radial strength and visibility.

"We are pleased to complete the enrollment phase of the EVOLVE clinical trial well ahead of schedule," said Professor Ian Meredith, M.B.B.S., Ph.D., Director of MonashHeart, Monash Medical Centre, Melbourne, Australia, and Principal Investigator of the trial.  "The brisk pace of enrollment reflects the strong interest in this innovative drug-eluting stent technolog
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientific Announces Agreement With Fukuda Denshi for Distribution of Cardiac Rhythm Management Products in Japan
2. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2010 Financial Results
3. Boston Scientific to Acquire Atritech
4. Boston Scientific Completes Enrollment in Clinical Trial Evaluating Next-Generation Nitinol Stent to Treat Iliac Artery Disease
5. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
6. Boston Scientific Completes Acquisition of Sadra Medical
7. Stryker Completes Acquisition of the Neurovascular Division of Boston Scientific
8. Boston Scientific Completes Sale of Neurovascular Business
9. Boston Scientific to Present at 29th Annual J.P. Morgan Healthcare Conference
10. Boston Scientific Announces Election of Dr. Kristina M. Johnson to its Board of Directors
11. Boston Scientific Welcomes Publication of Analysis of Patients Monitored by the LATITUDE® Patient Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
(Date:10/1/2014)... , Oct. 1, 2014 Quantum Materials ... volume production of photoactive quantum dots for use ... While offering numerous advantages for solar power generation, ... quantities of quantum dots with which to develop ... them from commercial utilization and acceptance. The company ...
(Date:10/1/2014)... Sophia Genetics, leader européen ... l,analyse des données issues du SNG (séquençage nouvelle ... in vitro (IVD) du gène CFTR permettant aux ... dans un seul essai SGN. La solution CE-IVD ... de variantes par l,intermédiaire d,un seul essai SGN, ...
Breaking Medicine Technology:NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3
... SADDLE BROOK, N.J., April 27, 2011 Okay, so ... day, but these two working moms are certainly creating ... two high-achieving working moms with formidable educational credentials on ... entrepreneurial detour, something truly unexpected happened...they started selling the ...
... 27, 2011 Wolters Kluwer Health, a leading ... and institutions in medicine, nursing, allied health and pharmacy, ... to acquire Lexi-Comp, Inc., a leading global provider of ... The acquisition is the latest in a series of ...
Cached Medicine Technology:Not Your Average Working Moms 2Wolters Kluwer Health to Acquire Leading Global Drug Information Provider Lexi-Comp 2Wolters Kluwer Health to Acquire Leading Global Drug Information Provider Lexi-Comp 3Wolters Kluwer Health to Acquire Leading Global Drug Information Provider Lexi-Comp 4
(Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
(Date:10/1/2014)... First Warning Systems, a pioneer in early ... the body, announced the company is changing its name ... breadth of upcoming product releases. The initial focus will ... “Our initial focus will be an ‘Internet of Everthing,’ ... cellular changes over time,” said Rob Royea, president and ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 Beverly ... Dr. Kathleen Mojas is celebrating 20 years of private ... assisted hundreds of people to achieve greater joy and ... important list of warning signs and suggestions for anyone ... Dr. Mojas explains: “Believe it or not, it’s ...
(Date:10/1/2014)... Diet Doc understands that many of their ... and their dieting attempts could be easily sabotaged by the ... diet treatments into their programs as a way to ... and effective weight loss results, it also allows patients to ... maintain their weight for the future. , Earlier versions of ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... rules for the first time forced players to limit the ... had to strategize how pitchers were used more carefully. ... under could throw up to six innings per week and ... in reported cases of young pitchers experiencing arm and shoulder ...
... 4 Health information,technology (HIT) is a powerful ... it must be implemented to interact with other ... to a new report by,BearingPoint, prepared for the ... a nonpartisan independent body based in Washington,but overseen ...
... Oct. 4 Hooper Holmes,(Amex: HH ) ... training,program for all paramedical examiners who have not ... training system,will be rolled out in November with ... same high quality education and training from the ...
... - Data Presented This Week at Major Medical Meeting Reinforce ... Broader Spectrum Pneumococcal ... division of Wyeth (NYSE: WYE ), comments on studies ... the Infectious Diseases,Society of America (IDSA) concerning PREVNAR(R) (Pneumococcal 7-valent,Conjugate ...
... Oct 4 Anesiva, Inc.,(Nasdaq: ANSV ) ... for the,investment community to review the company,s launch ... injection system. The briefing will take place on ... Eastern Time in New York City. To,access the ...
... Growth, ALISO VIEJO, Calif., Oct. 4 ... and services resource for,pathologists, oncologists and the pharmaceutical ... veteran Michael J. Pellini,M.D. has been named Chief ... to President and Chief Executive Officer,Ronald A. Andrews, ...
Cached Medicine News:Health News:How pitching changes little leaguers' shoulders 2Health News:How pitching changes little leaguers' shoulders 3Health News:New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care 2Health News:New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care 3Health News:New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care 4Health News:Portamedic Launches New Examiner Training Program 2Health News:Portamedic Launches New Examiner Training Program 3Health News:Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease 2Health News:Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease 3Health News:Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease 4Health News:Anesiva to Unveil Zingo(TM) Commercialization Plans 2Health News:Clarient Names Michael J. Pellini, M.D. Chief Operating Officer 2Health News:Clarient Names Michael J. Pellini, M.D. Chief Operating Officer 3Health News:Clarient Names Michael J. Pellini, M.D. Chief Operating Officer 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: